Barclays raised the firm’s price target on Natera (NTRA) to $270 from $230 and keeps an Overweight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the “most under-owned space in healthcare” creates a “great setup” for outperformance of the tools group in 2026, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera, Medica Scientia Innovation Research to collaborate on MiRaDoR study
- Natera announces initial translational research data from Phase 3 study
- Natera files to sell 1.95M shares of common stock for holders
- Natera Acquires Foresight Diagnostics for $275 Million
- Natera assumed with an Overweight at Morgan Stanley